BACKGROUND: Protease inhibitors (PIs) may be associated with accelerated atherosclerosis in individuals infected with human immunodeficiency virus (HIV). We assessed the effects of HIV PIs on subclinical atherosclerosis. METHODS: The lipid profiles, C-reactive protein (CRP) levels, coronary artery calcification (CAC) scores, and blood cell morphologic changes were quantified in 98 black adult participants, aged 25 to 45 years, with HIV-1 infection in Baltimore, Md. Fifty-five participants (56.1%) were taking PIs; 43 participants (43.9%) were not. The Student t and chi(2) tests were used as a means of detecting the between-group differences. RESULTS: Participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, heart rate, and red and white blood cell counts. Compared with the non-PI group, the PI group had significantly higher serum total cholesterol (4.8 +/- 1.0 vs 3.8 +/- 0.7 mmol/L, P <.001) and LDL cholesterol (2.9 +/- 0.8 vs 2.1 +/- 0.7 mmol/L, P <.001) levels and red blood cell mean corpuscular volume (92.2 +/- 9.3 vs 86.8 +/- 7.2 microm3, P =.048). The CAC scores in the PI group were also higher than those in the non-PI group (11.0 +/- 28.6 [n = 43] vs 1.7 +/- 5.8, P =.043). CAC scores were marginally associated with log-transformed duration of the PI therapy (P =.055). Serum CRP levels remained unchanged (5.5 +/- 13.6 mg/L [n = 45] vs 3.9 +/- 5.5 mg/L, P =.467). Serum total cholesterol level, LDL cholesterol level, red blood cell mean corpuscular volume, and CAC scores were indicated by means of regression analyses to be associated with log-transformed duration of the PI therapy. CONCLUSIONS: The use of PIs is associated with coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in individuals infected with HIV-1.
BACKGROUND: Protease inhibitors (PIs) may be associated with accelerated atherosclerosis in individuals infected with human immunodeficiency virus (HIV). We assessed the effects of HIV PIs on subclinical atherosclerosis. METHODS: The lipid profiles, C-reactive protein (CRP) levels, coronary artery calcification (CAC) scores, and blood cell morphologic changes were quantified in 98 black adult participants, aged 25 to 45 years, with HIV-1 infection in Baltimore, Md. Fifty-five participants (56.1%) were taking PIs; 43 participants (43.9%) were not. The Student t and chi(2) tests were used as a means of detecting the between-group differences. RESULTS:Participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, heart rate, and red and white blood cell counts. Compared with the non-PI group, the PI group had significantly higher serum total cholesterol (4.8 +/- 1.0 vs 3.8 +/- 0.7 mmol/L, P <.001) and LDL cholesterol (2.9 +/- 0.8 vs 2.1 +/- 0.7 mmol/L, P <.001) levels and red blood cell mean corpuscular volume (92.2 +/- 9.3 vs 86.8 +/- 7.2 microm3, P =.048). The CAC scores in the PI group were also higher than those in the non-PI group (11.0 +/- 28.6 [n = 43] vs 1.7 +/- 5.8, P =.043). CAC scores were marginally associated with log-transformed duration of the PI therapy (P =.055). Serum CRP levels remained unchanged (5.5 +/- 13.6 mg/L [n = 45] vs 3.9 +/- 5.5 mg/L, P =.467). Serum total cholesterol level, LDL cholesterol level, red blood cell mean corpuscular volume, and CAC scores were indicated by means of regression analyses to be associated with log-transformed duration of the PI therapy. CONCLUSIONS: The use of PIs is associated with coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in individuals infected with HIV-1.
Authors: Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Judith S Currier; Jens D Lundgren; Michael P Dubé; Steven E Lipshultz; Priscilla Y Hsue; Kathleen Squires; Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; Colleen M Hadigan; James H Stein; Robert H Eckel Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Hong Lai; Gary Gerstenblith; Elliot K Fishman; Jeffrey Brinker; Thomas Kickler; Wenjing Tong; Sundeepan Bhatia; Tai Hong; Shaoguang Chen; Ji Li; Barbara Detrick; Shenghan Lai Journal: Clin Infect Dis Date: 2012-03-15 Impact factor: 9.079
Authors: Susanna L Lamers; Marco Salemi; Derek C Galligan; Alanna Morris; Rebecca Gray; Gary Fogel; Li Zhao; Michael S McGrath Journal: J Neurovirol Date: 2010-05 Impact factor: 2.643
Authors: Janet Lo; Suhny Abbara; Leon Shturman; Anand Soni; Jeffrey Wei; Jose A Rocha-Filho; Khurram Nasir; Steven K Grinspoon Journal: AIDS Date: 2010-01-16 Impact factor: 4.177
Authors: Ivana Kennedy Parker; Ladeidra Monet Roberts; Laura Hansen; Rudolph L Gleason; Roy L Sutliff; Manu O Platt Journal: Ann Biomed Eng Date: 2014-04-10 Impact factor: 3.934
Authors: Alexandra Mangili; Denise L Jacobson; Jul Gerrior; Joseph F Polak; Sherwood L Gorbach; Christine A Wanke Journal: Clin Infect Dis Date: 2007-04-05 Impact factor: 9.079